{"disease":{"id":"poems-syndrome","name":"poems syndrome"},"drugs":{"marketed":[{"drug_id":"thalomid","indication_name":"Crow-Fukase (POEMS) syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Thalomid","company_name":"Ann & Robert H Lurie Children's Hospital of Chicago","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Protein cereblon","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"thalidomide","indication_name":"Crow-Fukase (POEMS) syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thalomid","generic_name":"THALIDOMIDE","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"thalidomide","quality_score":67,"revenue":null,"mechanism":"Thalomid works by inhibiting the production of tumor necrosis factor, a protein that promotes inflammation and tumor growth."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06040567","title":"Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study","phase":"","overall_status":"RECRUITING","enrollment_count":520,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT05476458","title":"To Evaluate Efficacy of Red Dichromatic Imaging (RDI) in Achieving Hemostasis During POEM Using GF 1500 UGI Scope","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Asian Institute of Gastroenterology, India","has_results":false},{"nct_id":"NCT07448935","title":"One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT05263817","title":"A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":75,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT04561557","title":"Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT06518876","title":"A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":21,"lead_sponsor_name":"Novatim Immune Therapeutics (Zhejiang) Co., Ltd.","has_results":false},{"nct_id":"NCT02921893","title":"Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07115654","title":"BCMA/CD3 BsAb Therapy for POEMS Syndrome","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT04396496","title":"Treatment of POEMS Syndrome With Daratumumab","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"University of Arkansas","has_results":true}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}